DOC

DOC (2,5-dimethoxy-4-chloroamphetamine) is a synthetic psychedelic belonging to the DOx series of substituted amphetamines. It was first synthesized by Alexander Shulgin and documented in PiHKAL (1991). DOC is among the longest-acting oral psychedelics in the DOx series, producing experiences of 18–30 hours with a pronounced amphetamine-type stimulant component alongside rich psychedelic effects. Active at doses of 1–3 mg, it carries the same class-defining risks as other DOx compounds: extreme duration, potent vasoconstriction, dangerous interaction with MAOIs, and potential for confusion with LSD on blotter paper markets.

Community experience with DOC — including trip reports and Reddit discussions — describes it as a powerful psychedelic that differs from LSD and psilocybin in several important dimensions: stronger stimulant body load, more pronounced visual structure, higher amphetamine-like character (jaw tension, appetite suppression, cardiovascular stimulation), and a duration that makes it among the most demanding psychedelics in widespread use. The chloro substitution at the 4-position (versus bromo in DOB) produces modest pharmacological differences in potency and possibly duration, with DOC generally regarded as slightly less potent than DOB by weight but more commercially prevalent as a research chemical.

How It Feels

DOC announces itself with patience. The first hour after ingestion offers little more than a faint quickening of the pulse and a barely perceptible brightness at the edges of vision, easily mistaken for placebo. But between the second and third hours, the world begins to change in earnest. Colors deepen and multiply, acquiring an almost liquid luminosity. The green of foliage becomes impossibly vivid, as though lit from within by its own private sun. Reds and oranges pulse with warmth. There is a stimulating undercurrent to the body, a clean, focused energy that differs from the jittery push of caffeine. The jaw tightens, the eyes widen, and awareness sharpens to a crystalline point.

By the time the peak establishes itself, typically around four to five hours in, DOC has revealed its defining character: an astonishing saturation of color combined with a lucid, exploratory headspace. The visual field is awash in chromatic intensity that many users describe as the most colorful experience of their lives. Surfaces shimmer with layered geometric patterns that shift and evolve continuously, but they do so with an almost playful lightness. There is less of the cosmic gravity of long-acting tryptamines here and more of a curious, aesthetically charged wonder. The mind feels sharp and capable of sustained attention, making DOC well suited to absorbing art, music, or complex conversation.

Physically, the stimulation is pronounced but manageable for most. Heart rate is elevated, body temperature runs warm, and there is a persistent restless energy that encourages movement. Walking, dancing, or simply pacing feels satisfying. Appetite is suppressed. The jaw clenches intermittently, and there may be an occasional wave of nausea, particularly during the come-up. Vasoconstriction can produce cold extremities and a slightly uncomfortable tension in the muscles. Despite these effects, the body generally feels functional and capable, not incapacitated.

The duration of DOC is its most significant practical feature. The peak alone stretches across four to eight hours, and the total experience, from first alert to baseline, typically spans twelve to twenty hours. The long tail is characterized by gradually fading visuals, a residual stimulation that keeps sleep at bay, and a gentle but persistent mental luminosity. Coming down from DOC does not feel like crashing so much as slowly dimming a very bright light. Sleep eventually arrives many hours later, and the following day may carry a quiet afterglow of enhanced color perception and emotional openness, tempered by physical exhaustion from the sheer duration of the ride.

Subjective Effects

The effects listed below are based on the Subjective Effect Index (SEI), an open research literature based on anecdotal reports and personal analyses. They should be viewed with a healthy degree of skepticism. These effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects.

Physical Effects

Physical(14)

Appetite suppression— A distinct decrease in hunger and desire to eat, ranging from reduced interest in food to complete d...
Dehydration— A state of insufficient bodily hydration manifesting as persistent thirst, dry mouth, and physical d...
Dry mouth— A persistent, uncomfortable reduction in saliva production causing the mouth and throat to feel parc...
Increased heart rate— A noticeable acceleration of heartbeat that can range from a subtle awareness of one's pulse to a fo...
Increased libido— A marked enhancement of sexual desire, arousal, and sensitivity to erotic stimuli that can range fro...
Laughter fits— Spontaneous, uncontrollable, and often prolonged episodes of intense laughter that erupt without any...
Nausea— An uncomfortable sensation of queasiness and stomach discomfort that may or may not lead to vomiting...
Physical euphoria— An intensely pleasurable bodily sensation that can manifest as waves of warmth, tingling electricity...
Pupil dilation— A visible enlargement of the pupil diameter (mydriasis) that can range from subtle widening to drama...
Sedation— A state of deep physical and mental calming that manifests as a progressive desire to remain still, ...
Seizure— Uncontrolled brain electrical activity causing convulsions and loss of consciousness -- a life-threa...
Stimulation— A state of heightened physical and mental energy characterized by increased wakefulness, elevated mo...
Teeth grinding— An involuntary clenching and rhythmic grinding of the jaw muscles, known clinically as bruxism, that...
Vasoconstriction— A narrowing of blood vessels throughout the body that produces sensations of cold extremities, tingl...

Tactile(1)

Tactile enhancement— The sense of touch becomes dramatically heightened, making physical contact feel intensely pleasurab...

Cognitive & Perceptual Effects

Visual(17)

After images— A visual phenomenon in which a faint, ghostly imprint of a previously viewed image persists in the v...
Brightness alteration— Perceived increase or decrease in environmental brightness beyond actual illumination levels, common...
Colour enhancement— An intensification of the brightness, vividness, and saturation of colors in the external environmen...
Colour shifting— The visual experience of colors on objects and surfaces cycling through continuous, fluid transforma...
Depth perception distortions— Alterations in how the distance of objects within the visual field is perceived, causing layers of s...
Diffraction— The experience of seeing rainbow-like spectrums of color and prismatic halos embedded within bright ...

Detection Methods

Urine Detection

DOC (4-chloro-2,5-dimethoxyamphetamine) is an amphetamine-derived psychedelic with a long duration of action and corresponding extended detection window. Due to its structural relationship to amphetamine, DOC and its metabolites may trigger presumptive positive results on standard amphetamine immunoassays. Urine detection windows are estimated at 2 to 4 days following ingestion when analyzed by immunoassay, and potentially longer with LC-MS/MS methods. The extended duration of action (up to 20 hours or more) means the body is eliminating parent compound and metabolites over a prolonged period.

Blood and Serum Detection

Blood detection windows for DOC are approximately 12 to 36 hours after oral ingestion, reflecting the compound's long pharmacological half-life. Peak plasma concentrations occur 2 to 4 hours post-ingestion. The slow offset of effects correlates with sustained measurable blood concentrations. LC-MS/MS provides the most sensitive and specific blood analysis.

Standard Drug Panel Inclusion

DOC is NOT specifically listed on standard 5-panel, 10-panel, or 12-panel drug screens. However, unlike most psychedelics, DOx-series amphetamines may cross-react with amphetamine immunoassays due to their intact amphetamine backbone. A presumptive positive for amphetamine on initial screening is a realistic possibility. On confirmatory testing by GC-MS or LC-MS/MS, the result would not confirm as amphetamine or methamphetamine, and would be reported as negative unless the laboratory specifically includes DOx compounds in their confirmatory panel. Most routine clinical laboratories do not test for DOx amphetamines.

Confirmatory Methods

Definitive identification of DOC requires GC-MS or LC-MS/MS with reference standards specific to DOx compounds. The amphetamine backbone makes GC-MS analysis straightforward without derivatization in most cases. Some forensic toxicology laboratories include DOx amphetamines in extended novel psychoactive substance panels. The relatively long detection window compared to other psychedelics provides a larger sampling window for confirmatory testing.

Reagent Testing (Harm Reduction)

The Marquis reagent produces variable color reactions with DOx amphetamines, ranging from orange-brown to olive-green depending on the specific compound. The Mecke reagent may produce blue-green to brown reactions. The Mandelin reagent typically shows green to brown. Critically, the Ehrlich reagent shows NO reaction with DOx amphetamines, which distinguishes them from lysergamides and tryptamines. Because DOx compounds are sometimes sold on blotter paper mimicking LSD, the Ehrlich test is an essential safety tool: absence of a purple reaction on blotter strongly suggests the substance is not LSD and may be a DOx compound or NBOMe. Given the very long duration of DOx compounds (12-24+ hours), correct identification prior to ingestion is important for safety planning.

Interactions

Substance	Status	Note
3-FMA	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
4-MMC	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
8-Chlorotheophylline	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Adrafinil	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Anandamide	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
APICA	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Atropa belladonna	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Benzydamine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Bromantane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabidiol	Caution	Cannabis can unpredictably intensify psychedelic effects and increase anxiety
Datura	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Dichloropane	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Diphenhydramine	Caution	Unpredictable compounding of hallucinogenic effects with anticholinergic delirium
Ephedrine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Harmala alkaloid	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Hexedrone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Methcathinone	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Nicotine	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Oxiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Peganum harmala	Caution	MAOIs dramatically potentiate psychedelics; drastically reduce dose and exercise extreme caution
Phenylpiracetam	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Rhodiola Rosea	Caution	Increases anxiety, cardiovascular stress, and psychological intensity
Cannabis	Uncertain	—
1,3-Butanediol	Low Risk & Synergy	Cross-tolerance exists; effects compound
25E-NBOH	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-2	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-21	Low Risk & Synergy	Cross-tolerance exists; effects compound
2C-T-7	Low Risk & Synergy	Cross-tolerance exists; effects compound
3-Cl-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-HO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCMo	Low Risk & Synergy	Produces unique synergistic effects; often combined
3-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
4-MeO-PCP	Low Risk & Synergy	Produces unique synergistic effects; often combined
Allylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ayahuasca	Low Risk & Synergy	Cross-tolerance exists; effects compound
Deschloroketamine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Diphenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
DiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
DOM	Low Risk & Synergy	Cross-tolerance exists; effects compound
DPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
Efavirenz	Low Risk & Synergy	Cross-tolerance exists; effects compound
Ephenidine	Low Risk & Synergy	Produces unique synergistic effects; often combined
EPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
HXE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Ibogaine	Low Risk & Synergy	Cross-tolerance exists; effects compound
Inhalants	Low Risk & Synergy	Produces unique synergistic effects; often combined
Memantine	Low Risk & Synergy	Produces unique synergistic effects; often combined
MET	Low Risk & Synergy	Cross-tolerance exists; effects compound
Methallylescaline	Low Risk & Synergy	Cross-tolerance exists; effects compound
MiPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MPT	Low Risk & Synergy	Cross-tolerance exists; effects compound
MXiPr	Low Risk & Synergy	Produces unique synergistic effects; often combined
O-PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
PCE	Low Risk & Synergy	Produces unique synergistic effects; often combined
Psilocybin Mushrooms	Low Risk & Synergy	Cross-tolerance exists; effects compound
Lorazepam	Low Risk & Decrease	Depressants dull psychedelic effects; benzodiazepines are commonly used as trip-killers

Showing 60 key interactions out of 79 total.

Toxicity & Safety

Extreme Duration Risk

The 18–30 hour duration of DOC means that all the risks of psychedelic use — bad psychological experiences, behavioral impairment, cardiovascular stimulation — are sustained for an unusually prolonged period. The inability to sleep during the experience, combined with the stimulant burden, produces significant physical exhaustion.

Vasoconstriction

DOC, like all DOx compounds, produces significant peripheral vasoconstriction. Severe cases present as cold, pale extremities with pain, and have been documented to require medical vasodilator treatment in high-dose scenarios. This represents a rare but serious physical toxicity not seen with indole psychedelics.

Cardiovascular Strain

Amphetamine-type cardiovascular stimulation sustained for 18–30 hours is the defining physical safety concern. Elevated heart rate and blood pressure over this duration represent substantial risk in individuals with cardiovascular risk factors.

Psychological Risks

The extended duration transforms any difficult psychological experience into an unusually prolonged ordeal. At higher doses, DOC can produce psychosis-like states with paranoia, thought disorder, and dissociation. These states, combined with the stimulant drive of the amphetamine scaffold, may produce agitated, unpredictable behavior.

Drug Interactions

MAOIs — severely potentiated toxicity; absolute contraindication
Lithium — unpredictable CNS effects, seizure risk
Stimulants — compounded cardiovascular strain over the multi-hour experience
Cannabis — frequently intensifies and disinhibits already strong effects unpredictably

Addiction Potential

not habit-forming

Overdose Information

Overdose

Internationally, DOC was added to the UN Convention on Psychotropic Substances as a Schedule II controlled substance in March 2020.

Austria: DOC is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).
Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.
Canada: DOC is Schedule I in Canada, making it illegal to sell, buy, or possess, without a valid legal exemption.
China: As of October 2015 DOC is a controlled substance in China.
Denmark: DOC is a Schedule I drug in Denmark.
Finland: DOC is illegal to possess, produce and sell in Finland.
Germany: DOC is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of February 1, 1997. It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.
Israel: The possession, production and sale is illegal.
Latvia: DOC is a Schedule I controlled substance.
New Zealand: DOC is a Class C drug in New Zealand.
Netherlands:** Possession, production and sale is illegal.
Switzerland: DOC can be considered a controlled substance as a defined derivative of a-Methylphenethylamine under Verzeichnis E point 130. It is legal when used for scientific or industrial use.
Turkey:** DOC is a classed as drug and is illegal to possess, produce, supply, or import.
United Kingdom: DOC is considered a Class A drug as a result of the amphetamine analogue clause of the Misuse of Drugs Act 1971.
United States: DOC is technically not scheduled in the United States, but could be considered an analogue of DOM or DOB and may therefore be considered a Schedule I drug under the Federal Analogue Act.
Responsible use
Psychedelics
DOx
DOB
DOI
DOC (Wikipedia)
DOC (Erowid Vault)
DOC (PiHKAL / Isomer Design)
Discussion
The Big & Dandy DOC Thread (Part 1) (Bluelight)

==Ref

Full	almost immediately after ingestion
Half	3 days
Zero	7 days

Quick Dosage

Dosage

insufflated

oral

Duration

insufflated

oral

How It Feels

Subjective Effects

Physical Effects

Physical(14)

Tactile(1)

Cognitive & Perceptual Effects

Visual(17)

Pharmacology

Mechanism of Action

Chloro vs. Bromo Substitution

Pharmacokinetics

Detection Methods

Urine Detection

Blood and Serum Detection

Standard Drug Panel Inclusion

Confirmatory Methods

Reagent Testing (Harm Reduction)

Interactions

History

Shulgin's Documentation

Research Chemical Prevalence

Legal Status

Harm Reduction

Identify the Substance

Dose Guidelines

Full-Day-Plus Planning

Managing the Stimulant Component

Recognizing Vasoconstriction

Toxicity & Safety

Extreme Duration Risk

Vasoconstriction

Cardiovascular Strain

Psychological Risks

Drug Interactions

Addiction Potential

Overdose Information

Tolerance

Cross-tolerances

Legal Status

Experience Reports (2)

Tips (10)

Community Discussions (6)

See Also

Similar by Effects

Same Class

References (6)

Frequently Asked Questions

Cognitive(13)

Auditory(3)

Multi-sensory(1)

Transpersonal(3)